Press release
Dyskinesia Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight
Dyskinesia Treatment Market
The Dyskinesia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dyskinesia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Dyskinesia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dyskinesia market.
Request for a Free Sample Report @ Dyskinesia Market Insight - https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of Dyskinesia Market Report are:
• According to DelveInsight, the Dyskinesia market size is expected to Grow at a decent CAGR by 2032
• In March 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
• In February 2025, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).
• In June 2024, Neurocrine Biosciences announced results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
• In May 2024, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea. Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is now available in 4 tablet strengths (30, 36, 42, and 48 mg), adding on to its original dosing options of 6 mg, 12 mg, and 24 mg.
• In June 2022, Mitsubishi Tanabe Pharma Corporation, announced to launch DYSVAL capsules 40mg, for treatment of tardive dyskinesia. This is the first drug to be approved for treatment of this rare disorder.
• Leading Dyskinesia companies working in the market are AbbVie, Addex Therapeutics Ltd, Adhera Therapeutics Inc, AEON Biopharma Inc, AfaSci Inc, Amarantus Bioscience, Astraea Therapeutics LLC, Bod Australia Ltd, Celon Pharma SA, Cerevance Inc, Cerevel Therapeutics, Contera Pharma ApS, Daewoong Pharmaceutical, DanPET AB, Domain Therapeutics SA, EpiVax Inc, ES Therapeutics LLC, GraySpace Therapeutics Inc, Hua Medicine Shanghai Ltd, Ipsen SA, IRLAB Therapeutics AB, Jazz Pharmaceuticals Plc, Junaxo Inc, Luye Pharma Group Ltd, MapLight therapeutics Inc, Merz Pharma GmbH & Co KgaA, MitoDys Therapeutics Ltd, Molomics Biotech SL, Motac Neuroscience Ltd, Neuralina Therapeutics Inc, Neurim Pharmaceuticals Ltd, Neurocea Pharmaceuticals, Neurocrine Biosciences Inc, Neurolixis Inc, Newron Pharmaceuticals SpA, Nine Square Therapeutics, Nissan Chemical Corp, Novartis AG, OB Pharmaceuticals, Peptron Inc, PharmaTher Holdings Ltd, PolyCore Therapeutics LLC, Praxis Precision Medicines, Puretech Health Plc, Revance Therapeutics Inc, Sage Therapeutics, SalubRx Therapeutics Inc, Shionogi & Co Ltd, Sinopia Biosciences Inc, SOM Biotech, Sumitomo Pharma Co Ltd, Tempero Bio, Teva Pharmaceutical, Trevi Therapeutics, Ultragenyx Pharmaceutical, VistaGen Therapeutics Inc, and Others.
Dyskinesia Overview
Dyskinesia (CVI) happens when your leg veins become damaged and can't work as they should. Normally, valves in your leg veins keep blood flowing back up to your heart. But CVI damages those valves, causing blood to pool in your legs. This increases pressure in your leg veins Dyskinesia refers to involuntary, abnormal movements that can affect different parts of the body, often resulting in excessive, uncontrolled motions such as twisting, writhing, or jerking. It is commonly associated with neurological disorders, particularly Parkinson's disease, where it arises as a side effect of long-term dopamine-replacement therapy, such as levodopa. Other causes include Huntington's disease, cerebral palsy, and medication-induced dyskinesia.
There are different types of dyskinesias, including tardive dyskinesia (caused by prolonged use of certain psychiatric drugs), chorea (characterized by sudden, dance-like movements), and dystonia (involving sustained muscle contractions). The severity of symptoms varies, ranging from mild to debilitating, significantly impacting a patient's quality of life.
Treatment for dyskinesia depends on the underlying cause. In Parkinson's disease, medication adjustments, extended-release formulations, or adjunctive therapies like amantadine can help manage symptoms. In severe cases, deep brain stimulation (DBS) may be considered. Emerging research on gene therapies, neuroprotective strategies, and personalized medicine holds promise for more effective management in the future.
Understanding dyskinesia is crucial for optimizing treatment plans and improving patient outcomes, making ongoing research and innovation in this field essential for better therapeutic solutions.
Learn more about Dyskinesia, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dyskinesia Market
The Dyskinesia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Dyskinesia market trends by analyzing the impact of current Dyskinesia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Dyskinesia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dyskinesia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Dyskinesia market in 7MM is expected to witness a major change in the study period 2019-2032.
Request a sample and discover more about the report offerings @ https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dyskinesia Epidemiology
The Dyskinesia epidemiology section provides insights into the historical and current Dyskinesia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Dyskinesia market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Dyskinesia Epidemiology @ https://www.delveinsight.com/sample-request/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dyskinesia Drugs Uptake
This section focuses on the uptake rate of the potential Dyskinesia drugs recently launched in the Dyskinesia market or expected to be launched in 2019-2032. The analysis covers the Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Dyskinesia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Dyskinesia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Dyskinesia Pipeline Development Activities
The Dyskinesia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Dyskinesia key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Dyskinesia pipeline development activities @ https://www.delveinsight.com/sample-request/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dyskinesia Therapeutics Assessment
Major key companies are working proactively in the Dyskinesia Therapeutics market to develop novel therapies which will drive the Dyskinesia treatment markets in the upcoming years are AbbVie, Addex Therapeutics Ltd, Adhera Therapeutics Inc, AEON Biopharma Inc, AfaSci Inc, Amarantus Bioscience, Astraea Therapeutics LLC, Bod Australia Ltd, Celon Pharma SA, Cerevance Inc, Cerevel Therapeutics, Contera Pharma ApS, Daewoong Pharmaceutical, DanPET AB, Domain Therapeutics SA, EpiVax Inc, ES Therapeutics LLC, GraySpace Therapeutics Inc, Hua Medicine Shanghai Ltd, Ipsen SA, IRLAB Therapeutics AB, Jazz Pharmaceuticals Plc, Junaxo Inc, Luye Pharma Group Ltd, MapLight therapeutics Inc, Merz Pharma GmbH & Co KgaA, MitoDys Therapeutics Ltd, Molomics Biotech SL, Motac Neuroscience Ltd, Neuralina Therapeutics Inc, Neurim Pharmaceuticals Ltd, Neurocea Pharmaceuticals, Neurocrine Biosciences Inc, Neurolixis Inc, Newron Pharmaceuticals SpA, Nine Square Therapeutics, Nissan Chemical Corp, Novartis AG, OB Pharmaceuticals, Peptron Inc, PharmaTher Holdings Ltd, PolyCore Therapeutics LLC, Praxis Precision Medicines, Puretech Health Plc, Revance Therapeutics Inc, Sage Therapeutics, SalubRx Therapeutics Inc, Shionogi & Co Ltd, Sinopia Biosciences Inc, SOM Biotech, Sumitomo Pharma Co Ltd, Tempero Bio, Teva Pharmaceutical, Trevi Therapeutics, Ultragenyx Pharmaceutical, VistaGen Therapeutics Inc, and Others.
Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dyskinesia Report Key Insights
1. Dyskinesia Patient Population
2. Dyskinesia Market Size and Trends
3. Key Cross Competition in the Dyskinesia Market
4. Dyskinesia Market Dynamics (Key Drivers and Barriers)
5. Dyskinesia Market Opportunities
6. Dyskinesia Therapeutic Approaches
7. Dyskinesia Pipeline Analysis
8. Dyskinesia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Dyskinesia Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Dyskinesia Competitive Intelligence Analysis
4. Dyskinesia Market Overview at a Glance
5. Dyskinesia Disease Background and Overview
6. Dyskinesia Patient Journey
7. Dyskinesia Epidemiology and Patient Population
8. Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Dyskinesia Unmet Needs
10. Key Endpoints of Dyskinesia Treatment
11. Dyskinesia Marketed Products
12. Dyskinesia Emerging Therapies
13. Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Dyskinesia Market Outlook (7 major markets)
16. Dyskinesia Access and Reimbursement Overview
17. KOL Views on the Dyskinesia Market
18. Dyskinesia Market Drivers
19. Dyskinesia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports:
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast
• Aesthetic Implants Market: https://www.delveinsight.com/blog/aesthetic-implants-market-outlook-and-key-trends
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Chronic Hepatitis Delta Virus Market: https://www.delveinsight.com/infographics/hepatitis-d-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dyskinesia Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight here
News-ID: 3942196 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Dyskinesia
Dyskinesia Market Emerging Trends and Growth Prospects 2034
Introduction
Dyskinesia, characterized by involuntary and uncontrolled movements, often arises as a side effect of long-term dopaminergic treatment in neurological disorders such as Parkinson's disease. As global cases of movement disorders continue to climb, so too does the need for therapies that effectively manage dyskinesia while preserving quality of life. The dyskinesia market has emerged as a critical segment of the wider central nervous system (CNS) therapeutics industry, shaped by aging…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Dyskinesia Pipeline involves 40+ key companies continuously working towards deve …
"DelveInsight's Dyskinesia Pipeline Insight 2022 report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in the Dyskinesia pipeline landscape"
It covers the Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dyskinesia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Dyskinesia Pipeline Report
• DelveInsight's Dyskinesia Pipeline…
Primary Ciliary Dyskinesia Pipeline: Insights into Novel Key Pharma Companies, G …
DelveInsight's, "Primary Ciliary Dyskinesia Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Primary Ciliary Dyskinesia Pipeline Report, detailed…
Tardive Dyskinesia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Resul …
Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor blocking drugs which are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum.
Download the sample report @ https://www.pharmaproff.com/request-sample/1106
The reasons that some people who take these drugs may get TD, and some people do not, is…
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to…
